Renovion is a pre-clinical stage pharmaceutical company with a therapy for chronic inflammatory airway diseases. The therapy is called Arina-1. Today, there are no FDA approved therapies for patients who have received a bilateral lung transplant. In the US, 1,800 lung transplants are performed annually in patients without other therapeutic options for their end-stage lung disease. Compared with other solid organ transplants, survival of lung transplant patients is poor, with only 50% surviving beyond 5 years and 20% beyond 10 years. This is likely due to the occurrence of progressive disease that is associated with pulmonary decline. We have evidence that Arina-1 will work in lung transplant and other patient populations via three patients on therapy under FDA approved investigator led INDs – one lung transplant, one CF, and one severe asthma patient. Llung transplant patients will be our initial indication, however, evidence suggests that we will be able to also help patients in other areas such as cystic fibrosis, asthma and chronic obstructive pulmonary disease (COPD). We are a pre-clinical stage pharma compound with which human outcomes relative to efficacy and safety have been demonstrated via over 15 years of cumulative human data.